Diarrhea is more common and sometimes more severe with flutamide than with other NSAAs.  In a comparative trial of combined androgen blockade for prostate cancer, the rate of diarrhea was 26% for flutamide and 12% for bicalutamide.  Moreover, 6% of flutamide-treated patients discontinued the drug due to diarrhea, whereas only % of bicalutamide-treated patients did so.  In the case of antiandrogen monotherapy for prostate cancer, the rates of diarrhea are 5–20% for flutamide, 2–5% for bicalutamide, and 2–4% for nilutamide .  In contrast to diarrhea, the rates of nausea and vomiting are similar among the three drugs.